Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.07), $0.15 better than the analyst estimate of ($1.22). Revenue for the quarter came in at $15.93 million versus the consensus estimate of $22.31 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.